Thursday, April 10, 2014
Another reason to believe Mannkind shares are overvalued
I already believe Mannkind is overvalued due to it's $2.5 billion market cap, weak balance sheet, and lack of commercial partner. Now they have another possible inhaled insulin competitor with a planned phase 3 trial next year. Take a look at Adam's article for the details.